In metastatic Grade 1 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), a higher burden of liver disease significantly reduces progression-free survival (PFS). Patients with concomitant extra-hepatic involvement have a lower overall survival (OS) rate. Liver tumor burden emerged as the sole predictor of PFS. These findings suggest a need for more aggressive treatment strategies in metastatic Grade 1 GEP-NETs, highlighting the importance of liver disease management in predicting prognosis.
Journal Article by Pandrowala SA, Kapoor D (…) Shrikhande SV et 10 al. in J Gastrointest Cancer
© 2024. The Author(s).